CD14 and rheumatoid arthritis: If combining the MTX and 0DMARD patients to one RA group (patients were not treated with any DMARD at baseline), the percentage of CD14+CD16++ monocytes (of monocytes) was lower in RA patients compared to HC (p = 0.03, Table S2).